Clinical Trial Update: Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates intrathecal rituximab combined with standard intrathecal prophylaxis to prevent CNS relapse in CD20+ non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab (intrathecal) (rituximab)

Snippet

Sponsor: Tahir Latif | Conditions: Non Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN